PortalPublikationenRelevance of serum sclerostin concentrations in critically i...

Relevance of serum sclerostin concentrations in critically ill patients

Standard

Relevance of serum sclerostin concentrations in critically ill patients. / Koch, Alexander; Weiskirchen, Ralf; Ludwig, Sebastian; Buendgens, Lukas; Bruensing, Jan; Yagmur, Eray; Baeck, Christer; Herbers, Ulf; Trautwein, Christian; Tacke, Frank.

in: J CRIT CARE, Jahrgang 37, 02.2017, S. 38-44.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Koch, A, Weiskirchen, R, Ludwig, S, Buendgens, L, Bruensing, J, Yagmur, E, Baeck, C, Herbers, U, Trautwein, C & Tacke, F 2017, 'Relevance of serum sclerostin concentrations in critically ill patients', J CRIT CARE, Jg. 37, S. 38-44. https://doi.org/10.1016/j.jcrc.2016.08.019

APA

Koch, A., Weiskirchen, R., Ludwig, S., Buendgens, L., Bruensing, J., Yagmur, E., Baeck, C., Herbers, U., Trautwein, C., & Tacke, F. (2017). Relevance of serum sclerostin concentrations in critically ill patients. J CRIT CARE, 37, 38-44. https://doi.org/10.1016/j.jcrc.2016.08.019

Vancouver

Koch A, Weiskirchen R, Ludwig S, Buendgens L, Bruensing J, Yagmur E et al. Relevance of serum sclerostin concentrations in critically ill patients. J CRIT CARE. 2017 Feb;37:38-44. https://doi.org/10.1016/j.jcrc.2016.08.019

Bibtex

@article{066abed3c1144a36b252a11effacfc6a,
title = "Relevance of serum sclerostin concentrations in critically ill patients",
abstract = "PURPOSE: Sclerostin is a negative regulator of bone metabolism and associated with chronic morbidities. We investigated circulating sclerostin in critically ill patients.METHODS: A total of 264 patients (170 with sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU) and on day 7. Patients' survival was followed for up to 3 years.RESULTS: Sclerostin serum levels were significantly elevated in critically ill patients at ICU admission compared with 99 healthy controls. Unlike in healthy controls, sclerostin did not depend on sex or age of ICU patients. Sclerostin was associated with disease severity, independent of the presence of sepsis. Sclerostin levels increased during the first week of treatment at the ICU but were not a predictor of mortality. Sclerostin was elevated in patients with preexisting chronic kidney disease or liver cirrhosis, but was not related to diabetes, obesity, or cardiovascular disease. Circulating sclerostin in ICU patients correlated with biomarkers reflecting renal, hepatic and cardiac dysfunction, and biomarkers reflecting bone metabolism.CONCLUSION: Serum sclerostin concentrations are significantly elevated in critically ill patients, linked to renal or hepatic organ failure, and associated with bone resorption markers, supporting its value as a potential tool for the assessment of ICU-related metabolic bone disease.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers/blood, Bone Diseases, Metabolic/blood, Bone Morphogenetic Proteins/blood, Cardiovascular Diseases/blood, Case-Control Studies, Critical Care, Critical Illness/mortality, Diabetes Mellitus/blood, Female, Genetic Markers, Humans, Intensive Care Units, Liver Cirrhosis/blood, Male, Middle Aged, Mortality, Obesity/blood, Prognosis, Prospective Studies, Renal Insufficiency, Chronic/blood, Sepsis/blood, Young Adult",
author = "Alexander Koch and Ralf Weiskirchen and Sebastian Ludwig and Lukas Buendgens and Jan Bruensing and Eray Yagmur and Christer Baeck and Ulf Herbers and Christian Trautwein and Frank Tacke",
note = "Copyright {\textcopyright} 2016 Elsevier Inc. All rights reserved.",
year = "2017",
month = feb,
doi = "10.1016/j.jcrc.2016.08.019",
language = "English",
volume = "37",
pages = "38--44",
journal = "J CRIT CARE",
issn = "0883-9441",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Relevance of serum sclerostin concentrations in critically ill patients

AU - Koch, Alexander

AU - Weiskirchen, Ralf

AU - Ludwig, Sebastian

AU - Buendgens, Lukas

AU - Bruensing, Jan

AU - Yagmur, Eray

AU - Baeck, Christer

AU - Herbers, Ulf

AU - Trautwein, Christian

AU - Tacke, Frank

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2017/2

Y1 - 2017/2

N2 - PURPOSE: Sclerostin is a negative regulator of bone metabolism and associated with chronic morbidities. We investigated circulating sclerostin in critically ill patients.METHODS: A total of 264 patients (170 with sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU) and on day 7. Patients' survival was followed for up to 3 years.RESULTS: Sclerostin serum levels were significantly elevated in critically ill patients at ICU admission compared with 99 healthy controls. Unlike in healthy controls, sclerostin did not depend on sex or age of ICU patients. Sclerostin was associated with disease severity, independent of the presence of sepsis. Sclerostin levels increased during the first week of treatment at the ICU but were not a predictor of mortality. Sclerostin was elevated in patients with preexisting chronic kidney disease or liver cirrhosis, but was not related to diabetes, obesity, or cardiovascular disease. Circulating sclerostin in ICU patients correlated with biomarkers reflecting renal, hepatic and cardiac dysfunction, and biomarkers reflecting bone metabolism.CONCLUSION: Serum sclerostin concentrations are significantly elevated in critically ill patients, linked to renal or hepatic organ failure, and associated with bone resorption markers, supporting its value as a potential tool for the assessment of ICU-related metabolic bone disease.

AB - PURPOSE: Sclerostin is a negative regulator of bone metabolism and associated with chronic morbidities. We investigated circulating sclerostin in critically ill patients.METHODS: A total of 264 patients (170 with sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU) and on day 7. Patients' survival was followed for up to 3 years.RESULTS: Sclerostin serum levels were significantly elevated in critically ill patients at ICU admission compared with 99 healthy controls. Unlike in healthy controls, sclerostin did not depend on sex or age of ICU patients. Sclerostin was associated with disease severity, independent of the presence of sepsis. Sclerostin levels increased during the first week of treatment at the ICU but were not a predictor of mortality. Sclerostin was elevated in patients with preexisting chronic kidney disease or liver cirrhosis, but was not related to diabetes, obesity, or cardiovascular disease. Circulating sclerostin in ICU patients correlated with biomarkers reflecting renal, hepatic and cardiac dysfunction, and biomarkers reflecting bone metabolism.CONCLUSION: Serum sclerostin concentrations are significantly elevated in critically ill patients, linked to renal or hepatic organ failure, and associated with bone resorption markers, supporting its value as a potential tool for the assessment of ICU-related metabolic bone disease.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers/blood

KW - Bone Diseases, Metabolic/blood

KW - Bone Morphogenetic Proteins/blood

KW - Cardiovascular Diseases/blood

KW - Case-Control Studies

KW - Critical Care

KW - Critical Illness/mortality

KW - Diabetes Mellitus/blood

KW - Female

KW - Genetic Markers

KW - Humans

KW - Intensive Care Units

KW - Liver Cirrhosis/blood

KW - Male

KW - Middle Aged

KW - Mortality

KW - Obesity/blood

KW - Prognosis

KW - Prospective Studies

KW - Renal Insufficiency, Chronic/blood

KW - Sepsis/blood

KW - Young Adult

U2 - 10.1016/j.jcrc.2016.08.019

DO - 10.1016/j.jcrc.2016.08.019

M3 - SCORING: Journal article

C2 - 27621111

VL - 37

SP - 38

EP - 44

JO - J CRIT CARE

JF - J CRIT CARE

SN - 0883-9441

ER -